Latest news with #RadiopharmTheranosticsLimited
Business Insider
6 days ago
- Business
- Business Insider
Bell Potter Sticks to Their Buy Rating for Radiopharm Theranostics Limited (RAD)
In a report released today, John Hester from Bell Potter maintained a Buy rating on Radiopharm Theranostics Limited (RAD – Research Report), with a price target of A$0.05. The company's shares closed today at A$0.03. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Hester is a 4-star analyst with an average return of 7.4% and a 50.57% success rate. Hester covers the Healthcare sector, focusing on stocks such as Polynovo , Mesoblast Limited, and Telix Pharmaceuticals. The analyst consensus on Radiopharm Theranostics Limited is currently a Hold rating.
Business Insider
24-05-2025
- Business
- Business Insider
Analysts' Top Healthcare Picks: Radiopharm Theranostics Limited Sponsored ADR (RADX), Mediwound (MDWD)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Radiopharm Theranostics Limited Sponsored ADR (RADX – Research Report) and Mediwound (MDWD – Research Report) with bullish sentiments. Confident Investing Starts Here: Radiopharm Theranostics Limited Sponsored ADR (RADX) JonesTrading analyst Justin Walsh reiterated a Buy rating on Radiopharm Theranostics Limited Sponsored ADR on May 22 and set a price target of $30.00. The company's shares closed last Friday at $4.81, close to its 52-week low of $3.55. According to Walsh is ranked 0 out of 5 stars with an average return of -5.4% and a 28.2% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Actinium Pharmaceuticals, and Perspective Therapeutics. The word on The Street in general, suggests a Hold analyst consensus rating for Radiopharm Theranostics Limited Sponsored ADR. Mediwound (MDWD) In a report issued on May 22, Michael Okunewitch from Maxim Group maintained a Buy rating on Mediwound, with a price target of $30.00. The company's shares closed last Friday at $20.37. According to Okunewitch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -19.5% and a 34.3% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Radiopharm Theranostics Limited Sponsored ADR, Acrivon Therapeutics, Inc., and Rani Therapeutics Holdings. Mediwound has an analyst consensus of Strong Buy, with a price target consensus of $28.67, a 43.5% upside from current levels. In a report issued on May 19, Craig-Hallum also initiated coverage with a Buy rating on the stock.
